PTGX (Protagonist Therapeutics) Construction In Progress: $0.00 Mil (As of Mar. 2026)


PTGX Protagonist Therapeutics Inc PTGX
51 GF Score
Price $122.58
GF Value $58.69
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Protagonist Therapeutics Construction In Progress?

Protagonist Therapeutics PTGX 51 Construction In Progress is $0.00 Mil as of Mar. 2026. GuruFocus rates PTGX with a GF Score™ of 51/100 and a GF Value™ of $58.69 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Protagonist Therapeutics Construction In Progress Historical Data

* Premium members only.

The historical data trend for Protagonist Therapeutics's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protagonist Therapeutics Construction In Progress Chart

Protagonist Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Protagonist Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
PTGX
51GF Score
Protagonist Therapeutics Inc PTGX
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Protagonist Therapeutics Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of $0.00 Mil mean?
Protagonist Therapeutics (PTGX) has a Construction In Progress of $0.00 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Protagonist Therapeutics and its competitors.
Is Protagonist Therapeutics' Construction In Progress too high?
Protagonist Therapeutics' current Construction In Progress is $0.00 Mil. Overall, Protagonist Therapeutics has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Protagonist Therapeutics' Construction In Progress compare to IMVT and SYRE?
Protagonist Therapeutics' Construction In Progress of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Protagonist Therapeutics and its competitors. Protagonist Therapeutics's current Construction In Progress is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagonist Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protagonist Therapeutics (PTGX) is currently considered Significantly Overvalued. The stock's GF Value™ is $58.69, compared to a current price of $122.58 — trading 108.9% above its estimated fair value. The current Construction In Progress is $0.00 Mil. Protagonist Therapeutics' overall GF Score™ is 51/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Protagonist Therapeutics (PTGX), the current Construction In Progress is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Protagonist Therapeutics (PTGX) Overvalued in 2026?

Based on GuruFocus' analysis, Protagonist Therapeutics stock appears to be overvalued. The current stock price of $122.58 is trading 108.9% above its estimated GF Value™ of $58.69. GuruFocus considers Protagonist Therapeutics to be Significantly Overvalued.

Key valuation signals for PTGX:

  • Construction In Progress: $0.00 Mil
  • GF Value™: $58.69 vs. price of $122.58 (108.9% above fair value)
  • GF Score™: 51/100 with 7 warning signs

No single metric tells the full story. See the PTGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Protagonist Therapeutics Business Description

Address 7707 Gateway Boulevard, Suite 140, Newark, CA, USA, 94560
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
51GF Score

Get the complete analysis for PTGX

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$122.58
Price
$58.69
GF Value